These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11551516)

  • 1. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples.
    Baker JR; Satarug S; Reilly PE; Edwards RJ; Ariyoshi N; Kamataki T; Moore MR; Williams DJ
    Biochem Pharmacol; 2001 Sep; 62(6):713-21. PubMed ID: 11551516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
    Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
    Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
    Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
    Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
    Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
    Taavitsainen P; Juvonen R; Pelkonen O
    Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
    Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol.
    Badawi AF; Cavalieri EL; Rogan EG
    Metabolism; 2001 Sep; 50(9):1001-3. PubMed ID: 11555828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
    Ueng YF; Hsieh CH; Don MJ
    Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver.
    Chang TK; Chen J; Pillay V; Ho JY; Bandiera SM
    Toxicol Sci; 2003 Jan; 71(1):11-9. PubMed ID: 12520071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Jones DR; Wrighton SA; Hall SD
    Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in zinc and copper homeostasis in human livers and kidneys associated with exposure to environmental cadmium.
    Satarug S; Baker JR; Reilly PE; Moore MR; Williams DJ
    Hum Exp Toxicol; 2001 Apr; 20(4):205-13. PubMed ID: 11393274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
    Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.